SCHEMBL5381302

SCHEMBL5381302

Cc1cc(N2C[C@@H]3C[C@H]2CN3C(=O)OC(C)(C)C)n2nc(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)c2n1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.39
PARP1 P09874 1/20 0.39
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 3/20 0.38
POLB P06746 2/20 0.38
HDAC1 Q13547 1/20 0.38
KCNK3 O14649 2/20 0.38
KCNK9 Q9NPC2 2/20 0.38
TP53 P04637 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.36
CNR1 P21554 2/20 0.36
CNR2 P34972 2/20 0.36
MAPK8 P45983 1/20 0.36
RET P07949 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5381366 0.89 MAPT (0.42) THRBHPGDSMN1; SMN2HSD17B10MAPT
SCHEMBL4838469 0.88 PARP1 (0.40) PARP1HDAC1KCNK3KCNK9CNR1
SCHEMBL5380182 0.81 HPGD (0.54) THRBHPGDSMN1; SMN2HSD17B10MAPT
SCHEMBL5380042 0.81 KMT2A (0.40) THRBHPGDSMN1; SMN2HSD17B10MAPT
SCHEMBL5390365 0.79 MAPT (0.39) THRBHPGDSMN1; SMN2HSD17B10MAPT
SCHEMBL5380294 0.79 THRB (0.43) THRBHPGDSMN1; SMN2HSD17B10MAPT
SCHEMBL5390372 0.78 MAPT (0.40) THRBHPGDSMN1; SMN2HSD17B10MAPT
SCHEMBL4845268 0.76 BRAF (0.39) HPGDSMN1; SMN2HSD17B10MAPTPOLB
SCHEMBL4833651 0.75 SLC6A7 (0.40) HPGDSMN1; SMN2HSD17B10TP53KMT2A
SCHEMBL4841441 0.74 CNR1 (0.34) MAPTCNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US claimed
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US claimed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
EP-1594872-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2005-11-16 EP disclosed
WO-2004069838-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2004-08-19 WO disclosed
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 THRB 383/4885PARP1 3506/4885HPGD 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.